Superior therapeutic index of calmangafodipir in comparison to mangafodipir as a chemotherapy adjunct

Translational Oncology

Volumn 5, Issue 6, 2012, Pages 492-502

  Karlsson, Jan Olof G ^a,b   Kurz, Tino ^a   Flechsig, Susanne ^c   Näsström, Jacques ^b   Andersson, Rolf G G ^a  

^a LINKÖPING UNIVERSITY   (Sweden)

^b PledPharma AB   (Sweden)

^c Experimental Pharmacology and Oncology Berlin Buch GmbH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM ION; CALFODIPIR; CALMANGAFODIPIR; FODIPIR; MANGAFODIPIR; MANGANESE SUPEROXIDE DISMUTASE; OXALIPLATIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CYTOTOXICITY; FEMALE; HUMAN; MALE; MASS SPECTROMETRY; MOUSE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OXIDATIVE STRESS; RAT; SINGLE DRUG DOSE; URINARY EXCRETION; ZINC BLOOD LEVEL;

EID: 84871687310     PISSN: None     EISSN: 19365233     Source Type: Journal    
DOI: 10.1593/tlo.12238     Document Type: Article

References (55)

1. Doroshow JH (2006). Redox modulation of chemotherapy-induced tumor cell killing and normal tissue toxicity [editorial]. J Natl Cancer Inst 98, 223-225.
2. Fridovich I (1998). Oxygen toxicity: a radical explanation. J Exp Biol 201, 1203-1209.
3. MacMillan-Crow LA, Crow JP, Kerby JD, Beckman JS, and Thompson JA (1996). Nitration and inactivation of manganese superoxide dismutase in chronic rejection of human renal allografts. Proc Natl Acad Sci USA 93, 11853-11858.
4. Agarwal R, Macmillan-Crow LA, Rafferty TM, Saba H, Roberts DW, Fifer EK, James LP, and Hinson JA (2010). Acetaminophen-induced hepatotoxicity in mice occurs with inhibition of activity and nitration of mitochondrial manganese superoxide dismutase. J Pharmacol Exp Ther 337, 110-118.
5. Buettner GR (2011). Superoxide dismutase in redox biology: the roles of superoxide and hydrogen peroxide. Anticancer Agents Med Chem 11, 341-346.
6. Ozden O, Park SH, Kim HS, Jiang H, Coleman MC, Spitz DR, and Gius D (2011). Acetylation of MnSOD directs enzymatic activity responding to cellular nutrient status or oxidative stress. Aging (Albany NY) 3, 102-107.
7. Anscher MS (2010). Targeting the TGF-β1 pathway to prevent normal tissue injury after cancer therapy. Oncologist 15, 350-359.
8. Kareva I (2011). What can ecology teach us about cancer? Transl Oncol 4, 266-270.
9. Urano M, Kuroda M, Reynolds R, Oberley TD, and St Clair DK (1995). Expression of manganese superoxide dismutase reduces tumor control radiation dose: gene-radiotherapy. Cancer Res 55, 2490-2493.
10. Borrelli A, Schiattarella A, Mancini R, Morrica B, Cerciello V, Mormile M, d'Alesio V, Bottalico L, Morelli F, D'Armiento M, et al. (2009). A recombinant MnSOD is radioprotective for normal cells and radiosensitizing for tumor cells. Free Radic Biol Med 46, 110-116.
11. Oberley LW (2001). Anticancer therapy by overexpression of superoxide dismutase. Antioxid Redox Signal 3, 461-472.
12. Laurent A, Nicco C, Chéreau C, Goulvestre C, Alexandre J, Alves A, Lévy E, Goldwasser F, Panis Y, Soubrane O, et al. (2005). Controlling tumor growth by modulating endogenous production of reactive oxygen species. Cancer Res 65, 948-956.
13. Karlsson JOG, Brurok H, Towart R, and Jynge P (2006). The magnetic resonance imaging contrast agent mangafodipir exerts antitumor activity via a previously described superoxide dismutase mimetic activity [letter to the editor]. Cancer Res 66, 598.
14. Alexandre J, Nicco C, Chéreau C, Laurent A, Weill B, Goldwasser F, and Batteux F (2006). Improvement of the therapeutic index of anticancer drugs by the superoxide dismutase mimic mangafodipir. J Natl Cancer Inst 98, 236-244.
15. Kurz T, Grant D, Andersson RGG, Towart R, De Cesare M, and Karlsson JOG (2012). Effects of MnDPDP and ICRF-187 on doxorubicin-induced cardiotoxicity and anticancer activity. Transl Oncol 5, 252-259.
16. Yri OE, Vig J, Hegstad E, Hovde O, Pignon I, and Jynge P (2009). Mangafodipir as a cytoprotective adjunct to chemotherapy-a case report. Acta Oncol 48, 633-635.
17. Karlsson JO, Adolfsson K, Thelin B, Jynge P, Andersson RG, and Falkmer UG (2012). First clinical experience with the magnetic resonance imaging contrast agent and superoxide dismutase mimetic mangafodipir as an adjunct in cancer chemotherapy-a translational study. Transl Oncol 5, 32-38.
18. Bedda S, Laurent A, Conti F, Chéreau C, Tran A, Tran-Van Nhieu J, Jaffray P, Soubrane O, Goulvestre C, Calmus Y, et al. (2003). Mangafodipir prevents liver injury induced by acetaminophen in the mouse. J Hepatol 39, 765-772.
19. Karlsson JOG (2004). Antioxidant activity of mangafodipir is not a new finding [letter to the editor]. J Hepatol 40, 872-873.
20. Scheuhammer AM and Cherian MG (1982). Influence of chronic MnCl2 and EDTA treatment on tissue levels and urinary excretion of trace metals in rats. Arch Environ Contam Toxicol 11, 515-520.
21. Toft KG, Hustvedt SO, Grant D, Martinsen I, Gordon PB, Friisk GA, Korsmo AJ, and Skotland T (1997). Metabolism and pharmacokinetics of MnDPDP in man. Acta Radiol 38, 677-689.
22. Southon TE, Grant D, Bjørnerud A, Moen OM, Spilling B, Martinsen I, and Refsum H (1997). NMR relaxation studies with MnDPDP. Acta Radiol 38, 708-716.
23. Wendland MF (2004). Applications of manganese-enhanced magnetic resonance imaging (MEMRI) to imaging of the heart. NMR Biomed 17, 581-594.
24. Brurok H, Ardenkjaer-Larsen JH, Hansson G, Skarra S, Berg K, Karlsson JO, Laursen I, and Jynge P (1999). Manganese dipyridoxyl diphosphate: MRI contrast agent with antioxidative and cardioprotective properties? Biochem Biophys Res Commun 254, 768-772.
25. Karlsson JOG, Brurok H, Eriksen M, Towart R, Toft KG, Moen O, Engebretsen B, Jynge P, and Refsum H (2001). Cardioprotective effects of the MR contrast agent MnDPDP and its metabolite MnPLED upon reperfusion of the ischemic porcine myocardium. Acta Radiol 42, 540-547.
26. Rocklage SM, Cacheris WP, Quay SC, Hahn FE, and Raymond KN (1989). Manganese(II) N, N '-dipyridoxylethylenediamine-N, N '-diacetate 5,5-bis (phosphate). Synthesis and characterization of a paramagnetic chelate for magnetic resonance imaging enhancement. Inorg Chem 28, 477-485.
27. Schmidt PP, Toft KG, Skotland T, and Andersson K (2002). Stability and transmetallation of the magnetic resonance contrast agent MnDPDP measured by EPR. J Biol Inorg Chem 7, 241-248.
28. Ni Y, Petré C, Bosmans H, Miao Y, Grant D, Baert AL, and Marchal G (1997). Comparison of manganese biodistribution and MR contrast enhancement in rats after intravenous injection of MnDPDP and MnCl2. Acta Radiol 38, 700-707.
29. Workman P, Aboagye EO, Balkwill F, Balmain A, Bruder G, Chaplin DJ, Double JA, Everitt J, Farningham DA, Glennie MJ, et al. (2010). Guidelines for the welfare and use of animals in cancer research. Br J Cancer 102, 1555-1577.
30. Crossgrove J and Zheng W (2004). Manganese toxicity upon overexposure. NMR Biomed 17, 544-553.
31. King JC, Shames DM, and Woodhouse LR (2000). Zinc homeostasis in humans. J Nutr 130, 1360S-1366S.
32. Folin M, Contiero E, and Vaselli GM (1994). Zinc content of normal human serum and its correlation with some hematic parameters. Biometals 7, 75-79.
33. Culotta VC, Yang M, and O'Halloran TV (2006). Activation of superoxide dismutases: putting the metal to the pedal. Biochim Biophys Acta 1763, 747-758.
34. Yuhas JM (1980). Active versus passive absorption kinetics as the basis for selective protection of normal tissues by S-2-(3-aminopropylamino)-ethylphosphorothioic acid. Cancer Res 40, 1519-1524.
35. Citrin D, Cotrim AP, Hyodo F, Baum BJ, Krishna MC, and Mitchell JB (2010). Radioprotectors and mitigators of radiation-induced normal tissue injury. Oncologist 15, 360-371.
36. Kang SK, Rabbani ZN, Folz RJ, Golson ML, Huang H, Yu D, Samulski TS, Dewhirst MW, Anscher MS, and Vujaskovic Z (2003). Overexpression of extracellular superoxide dismutase protects mice from radiation-induced lung injury. Int J Radiat Oncol Biol Phys 57, 1056-1066.
37. Oberley LW and Buettner GR (2003). Role of superoxide dismutase in cancer: a review. Cancer Res 39, 1141-1149.
38. Li C and Zhou HM (2011). The role of manganese superoxide dismutase in inflammation defense. Enzyme Res 2011, 387176. E-pub 2011 Oct 3.
39. Xu Y, Fang F, Dhar SK, Bosch A, St Clair WH, Kasarskis EJ, and St Clair DK (2008). Mutations in the SOD2 promoter reveal a molecular basis for an activating protein 2-dependent dysregulation of manganese superoxide dismutase expression in cancer cells. Mol Cancer Res 6, 1881-1893.
40. Zhang HJ, Yan T, Oberley TD, and Oberley LW (1999). Comparison of effects of two polymorphic variants of manganese superoxide dismutase on human breast MCF-7 cancer cell phenotype. Cancer Res 59, 6276-6283.
41. Irani K, Xia Y, Zweier JL, Sollott SJ, Der CJ, Fearon ER, Sundaresan M, Finkel T, and Goldschmidt-Clermont PJ (1997). Mitogenic signaling mediated by oxidants in Ras-transformed fibroblasts. Science 275, 1649-1652.
42. Cerutti PA (1985). Prooxidant states and tumor promotion. Science 227, 375-381.
43. Szatrowski TP and Nathan CF (1991). Production of large amounts of hydrogen peroxide by human tumor cells. Cancer Res 51, 794-798.
44. Benhar M, Dalyot I, Engelberg D, and Levitzki A (2001). Enhanced ROS production in oncogenically transformed cells potentiates c-Jun N-terminal kinase and p38 mitogen-activated protein kinase activation and sensitization to genotoxic stress. Mol Cell Biol 21, 6913-6926.
45. Cullen JJ, Weydert C, Hinkhouse MM, Ritchie J, Domann FE, Spitz D, and Oberley LW (2003). The role of manganese superoxide dismutase in the growth of pancreatic adenocarcinoma. Cancer Res 63, 1297-1303.
46. Behrend L, Mohr A, Dick T, and Zwacka RM (2005). Manganese superoxide dismutase induces p53-dependent senescence in colorectal cancer cells. Mol Cell Biol 25, 7758-7769.
47. Church SL, Grant JW, Ridnour LA, Oberley LW, Swanson PE, Meltzer PS, and Trent JM (1993). Increased manganese superoxide dismutase expression suppresses the malignant phenotype of human melanoma cells. Proc Natl Acad Sci USA 90, 3113-3117.
48. Zhong W, Oberley LW, Oberley TD, and St Clair DK (1997). Suppression of the malignant phenotype of human glioma cells by overexpression of manganese superoxide dismutase. Oncogene 14, 481-490.
49. Liu R, Oberley LW, and Oberley TD (1997). Transfection and expression of MnSOD cDNA decreases tumor malignancy of human oral squamous carcinoma SCC-25 cells. Hum Gene Ther 8, 585-595.
50. Li Y, Huang TT, Carlson EJ, Melov S, Ursell PC, Olson JL, Noble LJ, Yoshimura MP, Li N, Oberley TD, et al. (1998). Overexpression of manganese superoxide dismutase in DU145 human prostate carcinoma cells has multiple effects on cell phenotype. Prostate 35, 221-233.
51. Zitvogel L, Kepp O, and Kroemer G (2011). Immune parameters affecting the efficacy of chemotherapeutic regimens. Nat Rev Clin Oncol 8, 151-160.
52. Chua W, Charles KA, Baracos VE, and Clarke SJ (2011). Neutrophil/lymphocyte ratio predicts chemotherapy outcomes in patients with advanced colorectal cancer. Br J Cancer 104, 1288-1295.
53. Kensler TW, Bush DM, and Kozumbo WJ (1983). Inhibition of tumour promotion by a biomimetic SOD. Science 221, 75-81.
54. Asplund A, Grant D, and Karlsson JOG (1994). Mangafodipir (MnDPDP)-and MnCl2-induced endothelium-dependent relaxation in bovine mesenteric arteries. J Pharmacol Exp Ther 271, 609-618.
55. Miriyala S, Spasojevic I, Tovmasyan A, Salvemini D, Vujaskovic Z, St Clair D, and Batinic-Haberle I (2012). Manganese superoxide dismutase, MnSOD and its mimics. Biochim Biophys Acta 1822, 794-814.